Keyword: Fate Therapeutics

The AACR conference featured data on promising new approaches to CAR-T treatments and stimulating cancer-killing immune cells.

Scientists at Boston Children’s Hospital are developing a PD-L1-boosting therapy to curb the wayward autoimmune reaction that causes Type 1 diabetes.

The latest deal on the CAR-T front is between Juno partner Fate Therapeutics and the Memorial Sloan Kettering Cancer Center.